Biomarkers in gastroesophageal cancer 2025: an updated consensus statement by the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP).

IF 2.8 3区医学 Q2 ONCOLOGY

Clinical & Translational Oncology Pub Date : 2025-03-12 DOI:10.1007/s12094-025-03865-6

Maria Alsina Maqueda, Ana Teijo Quintáns, Miriam Cuatrecasas, Maria Jesús Fernández Aceñero, Ana Fernández Montes, Carlos Gómez Martín, Paula Jiménez Fonseca, Carolina Martínez Ciarpaglini, Fernando Rivera Herrero, Mar Iglesias Coma

{"title":"Biomarkers in gastroesophageal cancer 2025: an updated consensus statement by the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP).","authors":"Maria Alsina Maqueda, Ana Teijo Quintáns, Miriam Cuatrecasas, Maria Jesús Fernández Aceñero, Ana Fernández Montes, Carlos Gómez Martín, Paula Jiménez Fonseca, Carolina Martínez Ciarpaglini, Fernando Rivera Herrero, Mar Iglesias Coma","doi":"10.1007/s12094-025-03865-6","DOIUrl":null,"url":null,"abstract":"<p><p>Gastroesophageal carcinomas, including gastroesophageal adenocarcinoma (GEA) and esophageal squamous cell carcinoma (ESCC), pose a global health challenge due to their heterogeneity. The approach to diagnosis and treatment should first differentiate between GEA and ESCC. Over the past decade, therapies for metastatic or advanced GEA/ESCC have expanded, with several new therapeutic targets alongside trastuzumab for metastatic HER2-positive GEA. Four key biomarkers are essential for targeted therapy: HER2 overexpression/amplification, deficient mismatch repair/microsatellite instability (dMMR/MSI), PD-L1, and Claudin18.2 expression. Immunohistochemistry is the recommended method for these biomarkers evaluation. In addition, the assessment of biomarkers like FGFR2b is likely to become routine in the near future. Experts from the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM) have formed a consensus to optimize biomarker detection and usage in clinical practice. Their recommendations aim to improve personalized treatment strategies for GEA and ESCC patients, integrating new diagnostic insights into routine care.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical & Translational Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12094-025-03865-6","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Gastroesophageal carcinomas, including gastroesophageal adenocarcinoma (GEA) and esophageal squamous cell carcinoma (ESCC), pose a global health challenge due to their heterogeneity. The approach to diagnosis and treatment should first differentiate between GEA and ESCC. Over the past decade, therapies for metastatic or advanced GEA/ESCC have expanded, with several new therapeutic targets alongside trastuzumab for metastatic HER2-positive GEA. Four key biomarkers are essential for targeted therapy: HER2 overexpression/amplification, deficient mismatch repair/microsatellite instability (dMMR/MSI), PD-L1, and Claudin18.2 expression. Immunohistochemistry is the recommended method for these biomarkers evaluation. In addition, the assessment of biomarkers like FGFR2b is likely to become routine in the near future. Experts from the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM) have formed a consensus to optimize biomarker detection and usage in clinical practice. Their recommendations aim to improve personalized treatment strategies for GEA and ESCC patients, integrating new diagnostic insights into routine care.

查看原文本刊更多论文

2025年胃食管癌的生物标志物：西班牙医学肿瘤学会（SEOM）和西班牙病理学会（SEAP）的最新共识声明。

胃食管癌，包括胃食管腺癌（GEA）和食管鳞状细胞癌（ESCC），由于其异质性，构成了全球健康挑战。诊断和治疗方法应首先区分GEA和ESCC。在过去的十年中，转移性或晚期GEA/ESCC的治疗方法已经扩大，除了曲妥珠单抗外，还有几个新的治疗靶点用于转移性her2阳性GEA。四个关键的生物标志物是靶向治疗必不可少的：HER2过表达/扩增，缺陷错配修复/微卫星不稳定性（dMMR/MSI）， PD-L1和Claudin18.2表达。免疫组织化学是这些生物标志物评估的推荐方法。此外，FGFR2b等生物标志物的评估可能在不久的将来成为常规。来自西班牙病理学会（SEAP）和西班牙肿瘤医学学会（SEOM）的专家已经就优化临床实践中的生物标志物检测和使用达成共识。他们的建议旨在改善GEA和ESCC患者的个性化治疗策略，将新的诊断见解纳入常规护理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical & Translational Oncology 医学-肿瘤学

CiteScore

6.20

自引率

2.90%

发文量

240

审稿时长

1 months

期刊介绍： Clinical and Translational Oncology is an international journal devoted to fostering interaction between experimental and clinical oncology. It covers all aspects of research on cancer, from the more basic discoveries dealing with both cell and molecular biology of tumour cells, to the most advanced clinical assays of conventional and new drugs. In addition, the journal has a strong commitment to facilitating the transfer of knowledge from the basic laboratory to the clinical practice, with the publication of educational series devoted to closing the gap between molecular and clinical oncologists. Molecular biology of tumours, identification of new targets for cancer therapy, and new technologies for research and treatment of cancer are the major themes covered by the educational series. Full research articles on a broad spectrum of subjects, including the molecular and cellular bases of disease, aetiology, pathophysiology, pathology, epidemiology, clinical features, and the diagnosis, prognosis and treatment of cancer, will be considered for publication.